published meta-analysis   sensitivity analysis   studies

bamlanivimab/etesevimab in COVID 19 outpatients - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsBLAZE-1 phase 3 (combo), 2021 0.05 [0.00; 0.84] 0.05[0.00; 0.84]BLAZE-1 phase 3 (combo), 202110%1,035NAnot evaluable hospitalization or deathdetailed resultsBLAZE-1 phase 2 (combination with etesevimab), 2020 0.15 [0.02; 1.18] BLAZE-1 phase 3 (combo), 2021 0.29 [0.15; 0.58] 0.27[0.14; 0.52]BLAZE-1 phase 2 (combination with etesevimab), 2020, BLAZE-1 phase 3 (combo), 202120%1,303moderatenot evaluable viral clearance detailed resultsBLAZE-1 phase 2 (combination with etesevimab), 2020 1.65 [0.91; 3.00] 1.65[0.91; 3.00]BLAZE-1 phase 2 (combination with etesevimab), 202010%241NAnot evaluable viral clearance by day 7detailed resultsBLAZE-1 phase 2 (combination with etesevimab), 2020 1.31 [0.61; 2.83] 1.31[0.61; 2.83]BLAZE-1 phase 2 (combination with etesevimab), 202010%245NAnot evaluable emergent treatment-resistant variantsdetailed resultsBLAZE-1 phase 2 (combination with etesevimab), 2020 0.18 [0.02; 1.51] 0.18[0.02; 1.51]BLAZE-1 phase 2 (combination with etesevimab), 202010%254NAnot evaluable0.05.01.0relative treatment effectwww.metaEvidence.org2024-03-28 20:57 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 97 - treatments: 878 - roots T: 290